Core Viewpoint - The company, Yong'an Pharmaceutical (002365.SZ), has clarified that it does not currently develop or produce the drug Liraglutide, which has been inquired about for its potential use in weight loss and diabetes treatment [2][4]. Group 1: Company Operations - Yong'an Pharmaceutical primarily engages in three business areas: research, production, and sales of taurine products; research, production, and sales of health foods; and research, production, and sales of special dietary foods (creatine) [2][4]. - The company has not developed or produced Liraglutide products as of the latest update [2][4].

格隆汇12月2日丨永安药业(002365.SZ)在投资者互动平台表示，公司及子公司主要从事三类业务，一是 牛磺酸产品的研发、生产和销售；二是保健食品的研发、生产和销售；三是特殊膳食食品（肌酸）的研 发、生产和销售。目前暂未生产研发利莫那肽产品。 ...